June 13 Company Quick Takes: ISS rebuffs Takeda’s Weber; plus Sage, Blueprint, Tetraphase, Celgene and more
ISS weighs in on Weber
Institutional Shareholder Services recommended Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) shareholders oppose President and CEO Christophe Weber at the June 27 shareholder meeting because “top management is responsible for the company’s unfavorable” financial performance. In its report, the influential proxy advisory firm said Takeda had a five-year average return on equity of 3.2%, below the firm’s acceptable ROE threshold of 5%.
Zulresso ready for launch
The DEA has set Zulresso brexanolone from Sage Therapeutics Inc. (NASDAQ:SAGE) as a Schedule IV drug, keeping the postpartum depression drug on track for a late June launch (see “Sage Broadens the Spotlight on Postpartum Depression”)...